Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.68 |
| ▸ | HTR1A | P08908 | 3/20 | 0.59 |
| ▸ | HTR1D | P28221 | 2/20 | 0.59 |
| ▸ | HTR1B | P28222 | 2/20 | 0.59 |
| ▸ | HTR1F | P30939 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30644286 | 1.00 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL30096985 | 0.86 | HTR6 (0.56) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL505125 | 0.86 | HTR6 (0.56) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL3610149 | 0.83 | HTR6 (0.51) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL5746143 | 0.81 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL4019658 | 0.81 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL30229336 | 0.81 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL29686864 | 0.81 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL20843619 | 0.81 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL5758119 | 0.81 | HTR6 (1.00) | HTR6HTR1AHTR1DHTR1BHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025031471-A1 | NOVEL HETEROCYCLIC COMPOUND FOR REGULATING P53 FUNCTION | 德睿智药(苏州)新药研发有限公司 | 2025-02-13 | — | — | WO | disclosed |
| CN-117003770-A | Fused pyrimidine compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 南京师范大学 | 2023-11-07 | — | — | CN | disclosed |
| US-20200207741-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2020-07-02 | — | — | US | disclosed |
| US-10640491-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20180305340-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2018-10-25 | — | — | US | disclosed |
| US-10093657-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| EP-3080097-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | disclosed |
| EP-3080097-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | disclosed |
| WO-2007061694-A2 | SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-7087750-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2006-08-08 | — | — | US | disclosed |
| WO-2006031491-A2 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| CN-1714077-A | 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use | BIOVITRUM AB (SE) | 2005-12-28 | — | — | CN | disclosed |
| US-20050256106-A1 | Novel compounds, their use and preparation | BIOVITRUM AB, A STOCKHOLM, SWEDEN CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1373240-B1 | RETINOID X RECEPTOR MODULATORS | LILLY CO ELI (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040167160-A1 | Retinoid x receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
| EP-1326830-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| US-20020165251-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-11-07 | — | — | US | disclosed |
| WO-2002032863-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167160-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | HTR6 1111/4885HTR1A 899/4885HTR1D 1095/4885 |
| US-20180305340-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | HTR6 4290/4885HTR1A 4341/4885HTR1D 4159/4885 |
| US-10093657-B2 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | HTR6 4290/4885HTR1A 4341/4885HTR1D 4159/4885 |
| US-20020165251-A1 | Novel compounds, their use and preparation | HTR6, HTR1A, HTR5A | HTR6 1/4885HTR1A 2/4885HTR1D 16/4885 |
| US-20200207741-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | HTR6 3902/4885HTR1A 4018/4885HTR1D 3918/4885 |
| US-10640491-B2 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | HTR6 4290/4885HTR1A 4341/4885HTR1D 4159/4885 |
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | PSMG3, PSME1, PSMB1 | HTR6 4171/4885HTR1A 4083/4885HTR1D 4338/4885 |
| US-20050256106-A1 | Novel compounds, their use and preparation | HTR6, HTR3C, HTR1A | HTR6 1/4885HTR1A 3/4885HTR1D 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.